Nasus Pharma Ltd. (NYSE: NSRX) reported a net loss per share of $(0.54) for the six months ended June 30, 2026, missing the analyst consensus estimate of $(0.20) by 170%. This result represents a 217.65% increase in losses compared to the $(0.17) per share reported in the same period last year. The clinical-stage pharmaceutical company attributed the widened loss to accelerated research and development activities for its lead candidate, NS002, alongside costs associated with its recent transition to a public entity.

Despite the operational losses, Nasus strengthened its balance sheet through a private placement that generated gross proceeds of approximately $15.0 million. As of June 30, 2026, the company held $11.9 million in cash, cash equivalents, and short-term deposits, up from $4.3 million at the end of FY25. Management stated these reserves are sufficient to fund operations through the second quarter of 2027.

Financial Performance

Total operating expenses surged to $6.0 million in H1FY26, compared to $817,000 in H1FY25. This increase was driven by two primary factors:

• Research and Development (R&D): Expenses rose to $2.6 million from $0.3 million year-over-year. The company noted this increase was primarily attributable to costs paid in connection with the development of NS002, its intranasal epinephrine powder formulation for anaphylaxis.
• General and Administrative (G&A): Expenses climbed to $3.4 million from $0.5 million, mainly due to costs associated with becoming a public company.

The net loss per share was $0.54 (basic and diluted), compared to $0.17 in the prior year period. Interest income contributed $128,000 to the bottom line, while other expenses totaled $35,000.

What the Numbers Show

The financial data reveals a sharp divergence between capital inflow and operational expenditure. While the company raised approximately $15.0 million via equity financing, total operating expenses consumed $6.0 million in just six months. With $11.9 million in liquid assets and stated runway through Q2FY27, the current burn rate suggests limited headroom for extended development cycles without further funding or cost containment. Additionally, related-party transactions accounted for a notable portion of expenses, with $320,000 in R&D and $839,000 in G&A linked to related parties during the period.

Pipeline and Corporate Updates

Nasus provided updates on its key clinical programs:

• NS002: The company completed Phase 2 single and repeat dose studies, reporting statistically significant improvements in time to therapeutic threshold compared to EpiPen. A pivotal study is on track to initiate in the fourth quarter of 2026, with topline data expected in Q1FY27.
• NS003: Preclinical pharmacokinetic studies for this intranasal ondansetron formulation showed a favorable safety profile. A first-in-human PK study is scheduled to begin in the coming weeks.

In corporate governance news, Nasus appointed Brendan P. O’Grady as Chief Executive Officer, effective July 27, 2026. O’Grady brings over three decades of experience in global pharma leadership, including commercialization and strategic partnerships.

Nasus Pharma Ltd. (NYSE: NSRX) has appointed Brendan P. O'Grady as its Chief Executive Officer, marking a strategic leadership transition aimed at accelerating the commercialization of its intranasal drug portfolio. The appointment takes effect on July 27, 2026, with O'Grady succeeding Dan Teleman at the helm of the clinical-stage pharmaceutical company. This change signals a shift in focus toward maximizing the value of the firm's proprietary Nasax® intranasal technology platform and driving business development initiatives.

The leadership change positions Nasus Pharma to navigate its next phase of growth, specifically targeting the advancement of its product pipeline. O'Grady, described as a pharma industry veteran, will assume responsibility for steering the company's operational and strategic direction. The transition is designed to unlock the commercial potential of NS002, a key asset in the company's development roadmap.

Leadership Transition Details

The Board of Directors finalized the appointment to ensure continuity and strategic alignment for future growth objectives. The following table outlines the key details of the executive transition:

O'Grady's mandate includes advancing the company's pipeline and enhancing business development efforts. His background in the pharmaceutical industry is expected to support the execution of these priorities, particularly regarding the proprietary Nasax® technology.

Strategic Priorities

Upon assuming the role, O'Grady will prioritize several key areas critical to Nasus Pharma's long-term value creation. The primary focus remains on NS002, where the goal is to transition from clinical development toward commercial viability. Additionally, the new CEO will oversee the broader pipeline, ensuring that resources are allocated efficiently to advance promising candidates.

Business development initiatives are also central to the new strategy. By leveraging his industry experience, O'Grady aims to identify opportunities that can complement the company's existing assets and expand its market reach. This approach aligns with the company's broader objective of maximizing shareholder value through strategic partnerships and organic growth.

What the Numbers Show

While this announcement does not include immediate financial metrics, the appointment reflects a structural shift in Nasus Pharma's operational strategy. The focus on NS002 suggests that the company is nearing critical milestones in its development cycle, where commercial planning becomes as significant as clinical progress. Investors should monitor subsequent filings for updates on pipeline advancements and any associated capital requirements.